Company patents

Epizyme, Inc.

Epizyme, Inc. demonstrates a highly concentrated patent strategy, with 88.5% of its portfolio in Pharmaceutical Preparations, which saw a significant 31.6% YoY growth in 2024. However, a surprising shift is evident as patenting in its core areas, including Pharmaceutical Preparations, Heterocyclic Compounds (Pharma), and Therapeutic Activity (Pharma), experienced sharp declines of 64.0%, 50.0%, and 69.2% respectively in 2025, with only 1 patent filed in each of these categories so far in 2026, indicating a potential re-evaluation or slowdown in its R&D output.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

61 US filings (since 2023) · 9 categories · 9 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Pharmaceutical PreparationsHeterocyclic Compounds (Pharma)Acyclic / Carbocyclic Compounds
Who else files here? →
51since 2023
-70.8%YoY
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
19since 2023
-80.0%YoY
Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

Heterocyclic Compounds (Pharma)
Who else files here? →
15since 2023
-33.3%YoY
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
6since 2023
n/a
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Pharmaceutical PreparationsTherapeutic Activity (Pharma)
Who else files here? →
4since 2023
n/a
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
2since 2023
0.0%YoY
API Solid Form Engineering

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
2since 2023
0.0%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
n/a
Recombinant Protein & Peptide Therapeutics

Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.

Therapeutic Activity (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Showing 31-40 of 119

Page 4 of 12